Tags

Type your tag names separated by a space and hit enter

Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy.
J Urol. 2005 Dec; 174(6):2191-6.JU

Abstract

PURPOSE

Prostate specific antigen (PSA) is a useful marker for predicting outcomes following treatment for prostate cancer but, given the evolving nature of prostate cancer, there is an ongoing need to refine its use. We assessed preoperative PSA doubling time (PSADT) and PSA velocity (PSAV) as predictors of outcome following radical retropubic prostatectomy (RRP).

MATERIALS AND METHODS

We identified 2,290 men who were treated with RRP for prostate cancer between 1990 and 1999 with multiple preoperative PSA measurements available. PSADT was calculated by log linear regression and PSAV was calculated by linear regression. These parameters were used in preoperative and postoperative multivariate models for the end points of biochemical and clinical progression, and cancer death.

RESULTS

At a median followup of 7.1 years (range 0.1 to 14.5) biochemical progression, clinical progression and death from prostate cancer were observed in 583, 156 and 42 patients, respectively. The HR for death from prostate cancer was 6.22 (95% CI 3.33 to 11.61) in men with PSADT less than 18 months vs 18 or greater and 6.54 (95% CI 3.51 to 12.19) in men with PSAV greater than 3.4 ng/ml yearly vs 3.4 or less. On multivariate analysis adjusting for preoperative or postoperative variables PSADT and PSAV remained significant predictors of each outcome. When assessed jointly, PSAV was significant as a predictor of biochemical progression, while PSADT was a significant predictor of clinical progression and cancer death.

CONCLUSIONS

This study confirms the usefulness of preoperative PSA kinetics for predicting post-RRP outcomes, which may be useful for stratifying patients, so that rational management decisions can be made with respect to observation, intervention and adjuvant treatment. While PSADT maybe biologically more accurate and stronger on multivariate analysis, PSAV is clinically easier to use and a good approximation in the short term.

Authors+Show Affiliations

Department of Urology and Division of Biostatistics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

16280762

Citation

Sengupta, Shomik, et al. "Preoperative Prostate Specific Antigen Doubling Time and Velocity Are Strong and Independent Predictors of Outcomes Following Radical Prostatectomy." The Journal of Urology, vol. 174, no. 6, 2005, pp. 2191-6.
Sengupta S, Myers RP, Slezak JM, et al. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol. 2005;174(6):2191-6.
Sengupta, S., Myers, R. P., Slezak, J. M., Bergstralh, E. J., Zincke, H., & Blute, M. L. (2005). Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. The Journal of Urology, 174(6), 2191-6.
Sengupta S, et al. Preoperative Prostate Specific Antigen Doubling Time and Velocity Are Strong and Independent Predictors of Outcomes Following Radical Prostatectomy. J Urol. 2005;174(6):2191-6. PubMed PMID: 16280762.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. AU - Sengupta,Shomik, AU - Myers,Robert P, AU - Slezak,Jeffrey M, AU - Bergstralh,Eric J, AU - Zincke,Horst, AU - Blute,Michael L, PY - 2005/11/11/pubmed PY - 2006/9/16/medline PY - 2005/11/11/entrez SP - 2191 EP - 6 JF - The Journal of urology JO - J. Urol. VL - 174 IS - 6 N2 - PURPOSE: Prostate specific antigen (PSA) is a useful marker for predicting outcomes following treatment for prostate cancer but, given the evolving nature of prostate cancer, there is an ongoing need to refine its use. We assessed preoperative PSA doubling time (PSADT) and PSA velocity (PSAV) as predictors of outcome following radical retropubic prostatectomy (RRP). MATERIALS AND METHODS: We identified 2,290 men who were treated with RRP for prostate cancer between 1990 and 1999 with multiple preoperative PSA measurements available. PSADT was calculated by log linear regression and PSAV was calculated by linear regression. These parameters were used in preoperative and postoperative multivariate models for the end points of biochemical and clinical progression, and cancer death. RESULTS: At a median followup of 7.1 years (range 0.1 to 14.5) biochemical progression, clinical progression and death from prostate cancer were observed in 583, 156 and 42 patients, respectively. The HR for death from prostate cancer was 6.22 (95% CI 3.33 to 11.61) in men with PSADT less than 18 months vs 18 or greater and 6.54 (95% CI 3.51 to 12.19) in men with PSAV greater than 3.4 ng/ml yearly vs 3.4 or less. On multivariate analysis adjusting for preoperative or postoperative variables PSADT and PSAV remained significant predictors of each outcome. When assessed jointly, PSAV was significant as a predictor of biochemical progression, while PSADT was a significant predictor of clinical progression and cancer death. CONCLUSIONS: This study confirms the usefulness of preoperative PSA kinetics for predicting post-RRP outcomes, which may be useful for stratifying patients, so that rational management decisions can be made with respect to observation, intervention and adjuvant treatment. While PSADT maybe biologically more accurate and stronger on multivariate analysis, PSAV is clinically easier to use and a good approximation in the short term. SN - 0022-5347 UR - https://www.unboundmedicine.com/medline/citation/16280762/Preoperative_prostate_specific_antigen_doubling_time_and_velocity_are_strong_and_independent_predictors_of_outcomes_following_radical_prostatectomy_ L2 - https://www.jurology.com/doi/full/10.1097/01.ju.0000181209.37013.99?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -